These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2370833)

  • 1. Ocular findings in beta-thalassemia.
    Sorcinelli R; Sitzia A; Figus A; Lai ME
    Metab Pediatr Syst Ophthalmol (1985); 1990; 13(1):23-5. PubMed ID: 2370833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine.
    Rinaldi M; Della Corte M; Ruocco V; D'Onofrio C; Zanotta G; Romano A
    Metab Pediatr Syst Ophthalmol (1985); 1993; 16(1-2):23-5. PubMed ID: 8259071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.
    Taneja R; Malik P; Sharma M; Agarwal MC
    Indian J Ophthalmol; 2010; 58(2):125-30. PubMed ID: 20195035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular abnormalities in patients with beta thalassemia.
    Gartaganis S; Ismiridis K; Papageorgiou O; Beratis NG; Papanastasiou D
    Am J Ophthalmol; 1989 Dec; 108(6):699-703. PubMed ID: 2596550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Thalassemia and ocular implications: a systematic review.
    Liaska A; Petrou P; Georgakopoulos CD; Diamanti R; Papaconstantinou D; Kanakis MG; Georgalas I
    BMC Ophthalmol; 2016 Jul; 16():102. PubMed ID: 27390837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of ocular alterations in patients with β-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum.
    Barteselli G; Dell'arti L; Finger RP; Charbel Issa P; Marcon A; Vezzola D; Mapelli C; Cassinerio E; Cappellini MD; Ratiglia R; Viola F
    Ophthalmology; 2014 Mar; 121(3):709-18. PubMed ID: 24314836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E; Bianco I; Masi M
    Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract]   [Full Text] [Related]  

  • 8. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 9. Ocular abnormalities in multi-transfused beta-thalassemia patients.
    Jafari R; Heydarian S; Karami H; Shektaei MM; Dailami KN; Amiri AA; Rezaee MR; Far AA
    Indian J Ophthalmol; 2015 Sep; 63(9):710-5. PubMed ID: 26632126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lens opacities in thalassemia.
    Bloomfield SE; Markenson AL; Miller DR; Peterson CM
    J Pediatr Ophthalmol Strabismus; 1978; 15(3):154-6. PubMed ID: 739345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 12. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 13. Ocular changes in patients undergoing long-term desferrioxamine treatment.
    Arden GB; Wonke B; Kennedy C; Huehns ER
    Br J Ophthalmol; 1984 Dec; 68(12):873-7. PubMed ID: 6509007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of cataract formation in persons with beta-thalassemia].
    Popescu C; Siganos D; Zanakis E; Padakis A
    Oftalmologia; 1998; 45(4):10-3. PubMed ID: 10418622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine.
    Giardina PJ; Grady RW; Ehlers KH; Burstein S; Graziano JH; Markenson AL; Hilgartner MW
    Ann N Y Acad Sci; 1990; 612():275-85. PubMed ID: 2291555
    [No Abstract]   [Full Text] [Related]  

  • 16. Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: our experience.
    Jethani J; Marwah K; ; Patel S; Shah B
    Indian J Ophthalmol; 2010; 58(5):451-2. PubMed ID: 20689215
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of ocular abnormalities in patients with sickle hemoglobinopathies.
    Friberg TR; Young CM; Milner PF
    Ann Ophthalmol; 1986 Apr; 18(4):150-3. PubMed ID: 3592472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial exudative vitreoretinopathy.
    Benson WE
    Trans Am Ophthalmol Soc; 1995; 93():473-521. PubMed ID: 8719692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.